Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders - Trial NCT04695769
Access comprehensive clinical trial information for NCT04695769 through Pure Global AI's free database. This Phase 4 trial is sponsored by Helwan University and is currently Recruiting. The study focuses on Chronic Hepatitis C. Target enrollment is 400 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin
Interventional
drug
Sponsor & Location
Helwan University
Timeline & Enrollment
Phase 4
Nov 21, 2020
Nov 21, 2021
Primary Outcome
Achievement of sustained virological response (SVR)
Summary
This study aims to assess the role of ribavirin as an adjuvant to
 sofosbuvir/velpatasvir/voxilaprevir combination in retreatment of chronic hepatitis C with
 previous treatment failure.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04695769
Non-Device Trial